For EGFR-mutated patients with NSCLC who progress after EGFR-TKI treatment, a combination with immune checkpoint inhibitors (ICIs), chemotherapy, and anti-vascularization offers the greatest survival benefit, according to a statistical analysis of 2,085 patients in 17 studies (54). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.